Study to Assess the Safety of AZD1480 in Patients with Myeloproliferative Diseases

Exclusion Criteria

• - Prior therapy with any JAK2 medications
• - Significant lung disorder or lung disease
• - Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 28 days before study screening
• - Eye disease of the cornea
• - Patients requiring oxygen supplementation
• - Ejection fraction <45% (ECHO/MUGA) or significant pulmonary hypertension >40 mm Hg (by Echo/Doppler)
• - Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) <70% predicted or >130% predicted
• - Diffusing capacity of the Lung for Carbon Monoxide (DLCO) corrected for hemoglobin <60% predicted, oxygen saturation <88% at rest or after a 6-minute flat walk, without supplemental oxygen
• - Chest infection requiring antibiotics within 7 days of the first dose of Investigational product.